ReviewLeukemia2002
Classical and novel retinoids: their targets in cancer therapy.
Review in Leukemia, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 125 citations in OpenAlex.
- Phase II trial of fenretinide in advanced renal carcinoma.Investigational new drugs · 2005Trial
- Revealing the Potential Application of EC-Synthetic Retinoid Analogues in Anticancer Therapy.Molecules (Basel, Switzerland) · 2021Article
- Restoration of ceramide de novo synthesis by the synthetic retinoid ST1926 as it induces adult T-cell leukemia cell death.Bioscience reports · 2020Article
- Structure-Activity Relationship and Anticancer Profile of Second-Generation Anti-MRSA Synthetic Retinoids.ACS medicinal chemistry letters · 2020Article
- Extent of Food Processing and Risk of Prostate Cancer: The PROtEuS Study in Montreal, Canada.Nutrients · 2020Article
- Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.Cancer chemotherapy and pharmacology · 2019Article
- Detection of retinoid receptors in non-neoplastic canine lymph nodes and in lymphoma.The Canadian veterinary journal = La revue veterinaire canadienne · 2014Article
- The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.Chemical reviews · 2013Review
- Article
- A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.Investigative ophthalmology & visual science · 2013Article
- Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment.Drug discovery today. Therapeutic strategies · 2013Article
- Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus.Breast cancer research and treatment · 2012Article
- In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines.Cancer cell international · 2011Article
- Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis.American journal of physiology. Endocrinology and metabolism · 2009Article
- Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles.European journal of medicinal chemistry · 2009Article
- Vitamin A metabolism is impaired in human ovarian cancer.Gynecologic oncology · 2009Article
- Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.Journal of translational medicine · 2009Article
- Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene).Cancer science · 2008Article
- Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent.BMC cancer · 2007Article
- Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.Bioorganic & medicinal chemistry · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Retinoids are important mediators of cellular growth and differentiation. Retinoids modulate the growth of both normal and malignant cells through their binding to retinoid nuclear receptors and their subsequent activation. While retinoids have demonstrated therapeutic efficacy in the treatment of acute promyelocytic leukemia, their spectrum of activity remains limited. Other agents such as histone deacetylase inhibitors may significantly increase retinoid activity in a number of malignant cell types. The novel retinoids N-(4-hydroxyphenyl) retinamide (4-HPR) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN) induce apoptosis in a wide variety of malignant cells. Their mechanism(s) of action remain unclear, although a number of potential targets have been identified. Whether the retinoid receptors are involved in 4-HPR and CD473/AHPN mediated apoptosis remains unclear. Both 4-HPR and CD437/AHPN display significant potential as therapeutic agents in the treatment of a number of premalignant and malignant conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.